2. Membrane Transporter/Ion Channel Immunology/Inflammation Others
  3. P2X Receptor Interleukin Related Fluorescent Dye
  4. TNP-ATP triethylammonium

TNP-ATP triethylammonium is a P2X receptor antagonist with an IC50 of 0.010 μM for P2X3 and an IC50 of 0.062 μM for P2X2/3. TNP-ATP triethylammonium acts as an inhibitor of CheA autophosphorylation, with a Ki of 0.7 µM. TNP-ATP triethylammonium blocks the functional activation of P2X1-7 receptors. TNP-ATP triethylammonium attenuates hypoxia-induced IL-1β expression and release. TNP-ATP triethylammonium alleviates visceral pain, and improves hypoxia-induced cognitive impairment, insufficient myelination and neuroinflammation. Binding of TNP-ATP triethylammonium to CheA enhances the fluorescence of the TNP group. TNP-ATP triethylammonium can be used in studies related to visceral pain. NP-ATP triethylammonium can be used in studies related to hypoxia-induced insufficient myelination and cognitive decline.

For research use only. We do not sell to patients.

TNP-ATP triethylammonium

TNP-ATP triethylammonium Chemical Structure

CAS No. : 61368-63-6

Size Price Stock Quantity
Solvent
1 mg (10 mM * 89.05 μL in Water) In-stock

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Other Forms of TNP-ATP triethylammonium:

TNP-ATP triethylammonium Related Antibodies

Top Publications Citing Use of Products

View All P2X Receptor Isoform Specific Products:

View All Isoforms
P2X1 Receptor P2X2 Receptor P2X3 Receptor P2X4 Receptor P2X7 Receptor

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

TNP-ATP triethylammonium is a P2X receptor antagonist with an IC50 of 0.010 μM for P2X3 and an IC50 of 0.062 μM for P2X2/3. TNP-ATP triethylammonium acts as an inhibitor of CheA autophosphorylation, with a Ki of 0.7 µM. TNP-ATP triethylammonium blocks the functional activation of P2X1-7 receptors. TNP-ATP triethylammonium attenuates hypoxia-induced IL-1β expression and release. TNP-ATP triethylammonium alleviates visceral pain, and improves hypoxia-induced cognitive impairment, insufficient myelination and neuroinflammation. Binding of TNP-ATP triethylammonium to CheA enhances the fluorescence of the TNP group. TNP-ATP triethylammonium can be used in studies related to visceral pain. NP-ATP triethylammonium can be used in studies related to hypoxia-induced insufficient myelination and cognitive decline[1][2].

IC50 & Target[1][2]

P2X3 Receptor

0.010 μM (IC50)

P2X2/3

0.062 μM (IC50)

IL-1β

 

In Vitro

TNP-ATP triethylammonium (3 min) potently blocks agonist-mediated activation of recombinant P2X3 receptors (IC50 = 0.010 μM) and recombinant P2X2/3 receptors (IC50 = 0.062 μM) in 1321N1 cells by inhibiting cytoplasmic calcium influx[1].
TNP-ATP triethylammonium attenuates hypoxia-induced IL-1β expression and release in vitro[2].
TNP-ATP triethylammonium binds to the dimer of E. coli CheA (H48Q mutant), with macroscopic dissociation constants of Kd1 = 0.4 µM and Kd2 = 1.8 µM[3].
TNP-ATP (0.66-9.9 µM) triethylammonium potently inhibits autophosphorylation of wild-type E. coli CheA, with a competitive inhibition constant (Ki) of 0.7 µM[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TNP-ATP triethylammonium Related Antibodies
In Vivo

TNP-ATP (1.28-128 μmol/kg; i.p.; single dose) triethylammonium dose-dependently blocks acetic acid-induced visceral pain in mice with an ED50 of 6.35 μmol/kg (i.p.), completely eliminating nociceptive behavior at the highest tested dose and showing potency comparable to morphine[1].
TNP-ATP (1-8 mg/kg; i.p.; single dose; 2 h after hypoxia exposure) triethylammonium significantly ameliorates hypoxia-induced cognitive dysfunction, hypomyelination, neuroinflammation, and glutamate deregulation, with peak efficacy across all measured endpoints at 2 mg/kg[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 129J (adult male, 20-25 g)[1]
Dosage: 1.28 μmol/kg; 12.8 μmol/kg; 38.4 μmol/kg; 128 μmol/kg
Administration: i.p.; single dose (3 minutes prior to acetic acid injection)
Result: Reduced acetic acid-induced abdominal constrictions dose-dependently, with an ED50 of 6.35 μmol/kg (i.p.).
Completely abolished nociceptive behavior at 128 μmol/kg (i.p.).
Showed antinociceptive potency comparable to morphine (ED50=3 μmol/kg, i.p.), and 6-10 fold greater than suramin and PPADS, and 10 fold greater than TNP-AMP.
Animal Model: Sprague-Dawley (postnatal day 0, either sex; male used for P30 Y-maze, P45 Morris water maze, and P60 MRI DTI testing; neonatal hypoxic brain injury model)[2]
Dosage: 1 mg/kg; 2 mg/kg; 4 mg/kg; 8 mg/kg
Administration: i.p.; single dose; 2 h after hypoxia exposure
Result: Reduced days needed to reach learning criterion in Y-maze test (P30 male rats) in a dose-dependent manner, with peak efficacy at 2 mg/kg (P < 0.01 vs hypoxia-only group).
Increased time spent in target quadrant and number of platform location crossings in Morris water maze test (P45 male rats) at 2 mg/kg (P < 0.05 vs hypoxia-only group), reversing hypoxia-induced spatial memory deficits.
Attenuated hypoxia-induced expansion of septum and lateral ventricles, restored destroyed myelin structure in corpus callosum (CC), and fully restored fractional anisotropy (FA) values in CC and middle corpus callosum (MCC) to normal control levels at 2 mg/kg (P < 0.01 vs hypoxia-only group) in MRI DTI scanning (P60 male rats).
Reduced hypoxia-induced elevation of IL-1β protein levels in brain tissue at 1 day post-hypoxia at 2 mg/kg (P < 0.05 vs hypoxia-only group).
Prevented hypoxia-induced glutamate elevation in periventricular zone at both 4 h and 1 day post-hypoxia at 2 mg/kg (P < 0.01 at 4 h, P < 0.05 at 1 day vs hypoxia-only group).
Molecular Weight

1123.03

Formula

C40H77N12O19P3
CAS No.
Appearance

Liquid

Color

Orange to red

SMILES

CCN(CC)CC.CCN(CC)CC.CCN(CC)CC.CCN(CC)CC.NC1=NC=NC2=C1N=CN2[C@H](O3)[C@H](O4)[C@H](OC54C([N+]([O-])=O)=CC([N+]([O-])=O)=CC5[N+]([O-])=O)[C@H]3COP(O)(OP(OP(O)(O)=O)(O)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Solution, -20°C, 2 years
Purity & Documentation

Purity: 98.7%

SDS (251 KB)

COA (251 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

TNP-ATP triethylammonium Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TNP-ATP61368-63-6P2X ReceptorInterleukin RelatedFluorescent DyeP2XRsILhuman P2X31321N1 cellsvisceral painP2X receptorrat P2X1neonatal hypoxia-induced hypomyelinationcognitive declineIL-1βEscherichia coli CheAhuman P2X2/3Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TNP-ATP triethylammonium
Cat. No.:
HY-108667
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.